PATIENTS WITH ANTICARDIOLIPIN ANTIBODIES WITH AND WITHOUT ANTIPHOSPHOLIPID SYNDROME - THEIR CLINICAL-FEATURES AND BETA-2-GLYCOPROTEIN-I PLASMA-LEVELS
PATIENTS WITH ANTICARDIOLIPIN ANTIBODIES WITH AND WITHOUT ANTIPHOSPHOLIPID SYNDROME - THEIR CLINICAL-FEATURES AND BETA-2-GLYCOPROTEIN-I PLASMA-LEVELS
复制标题
DOI：
10.1111/j.1365-2362.1992.tb01494.x
复制
发表时间：
1992-07-01
影响因子：
5.5
通讯作者：
MOUTSOPOULOS, HM
中科院分区：
文献类型：
--
作者：
VLACHOYIANNOPOULOS, PG;KRILIS, SA;MOUTSOPOULOS, HM
对38例ACL阳性患者和45例ACL阴性患者的临床和血清学特征进行了比较。在ACL阳性的患者中，血栓性静脉炎和网状活体的发生率显著增加。合并血栓性静脉炎和/或动脉血栓的ACL阳性患者13例，其中13例为抗磷脂综合征(APS)，70例为系统性红斑狼疮(SLE)。与SLE患者相比，APS患者动脉闭塞、反复流产和中风的发生率也较高。血清Ig G-ACL水平高的患者更易发生APS，而仅有Ig G-ACL或Ig M-ACL水平低的患者更容易发生无APS临床特征的SLE。由于最近发现ACL抗体与磷脂结合的血浆蛋白β-2-糖蛋白-I(β-2-GPI)相互作用，我们测量了这些患者的β-2-GPI水平，发现APS患者的β-2-GPI水平显著高于ACL抗体阴性的SLE患者。由于已知β-2-GPI在凝血过程中发挥多种作用，ACL抗体与这种糖蛋白的相互作用可能在APS中起致病作用。
The clinical and serological features of 38 aCL-positive patients were compared to those of 45 aCL-negative patients. A significantly higher incidence of thrombophlebitis and livedo reticularis was found in aCL-positive patients. There were 13 aCL positive patients with thrombophlebitis and/or arterial thromboses and these 13 patients were designated as having the antiphospholipid syndrome (APS) while the remaining 70 patients were diagnosed as having Systemic Lupus Erythematosus (SLE). APS patients also had a high incidence of arterial occlusions, recurrent abortions and strokes compared to SLE patients. Patients with high levels of IgG-aCL were more likely to have APS, while patients with low levels of IgG-aCL or IgM-aCL only were more likely to have SLE without the clinical features of APS. Since aCL antibodies have recently been shown to interact with a phospholipid-binding plasma protein beta-2-glycoprotein-I (beta-2-GPI), we measured the beta-2-GPI levels in these patients and found that beta-2-GPI levels are significantly higher in APS compared to SLE patients negative for aCL antibodies. Since beta-2-GPI is known to exert multiple effects on coagulation processes the interaction of aCL antibodies with this glycoprotein may play a pathogenic role in APS.